Professor Rong Fu: From Data to Mechanism—A Comprehensive Interpretation of Thrombosis in PNH and Emerging Strategies for Prevention and Management

Professor Rong Fu: From Data to Mechanism—A Comprehensive Interpretation of Thrombosis in PNH and Emerging Strategies for Prevention and Management

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was held in Beijing, bringing together leading experts from China and abroad to discuss advances in thrombosis, hemostasis, hematologic malignancies, and immunology.
North–South Summit 2026 | Professor Leiping Wang: HER2-Positive Metastatic Breast Cancer—Has the First-Line ADC Era Truly Arrived?

North–South Summit 2026 | Professor Leiping Wang: HER2-Positive Metastatic Breast Cancer—Has the First-Line ADC Era Truly Arrived?

With the release of data from studies such as DESTINY-Breast09 (DB-09), antibody–drug conjugates (ADCs) are gaining increasing prominence in the first-line treatment of HER2-positive metastatic breast cancer (MBC). However, while the traditional THP regimen (trastuzumab + pertuzumab + taxane) remains firmly established as the guideline-preferred standard, the question remains: has the “era of ADC dominance” truly begun? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Leiping Wang from Fudan University Shanghai Cancer Center addressed this question. She emphasized that although ADCs have opened the door to first-line therapy with impressive progression-free survival (PFS) benefits, their full integration into clinical practice still requires further validation, particularly in the context of refined disease management and treatment sequencing.
Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

Breaking News: Academician Binghe Xu Leads PHILA Study Published in The BMJ—A “China Solution” for First-Line Dual Targeting in HER2-Positive Metastatic Breast Cancer

On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan Cancer Hospital) as co–first authors. With a median follow-up of 45.5 months, the study demonstrated that first-line treatment with pyrotinib in combination with trastuzumab and docetaxel significantly improved overall survival (OS) in patients with HER2-positive metastatic breast cancer, reducing the risk of death by 26%. These findings establish a dual-targeted regimen that reflects a distinct “China-developed strategy” for first-line treatment in this population.
North–South Summit 2026 | Professor Hao Wang: When Is the Optimal Timing for Precision Endocrine Testing in HR+/HER2– Metastatic Breast Cancer?

North–South Summit 2026 | Professor Hao Wang: When Is the Optimal Timing for Precision Endocrine Testing in HR+/HER2– Metastatic Breast Cancer?

Precision testing is only as valuable as its timing. During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Hao Wang from Sichuan Cancer Hospital delivered a focused presentation on the optimal timing of endocrine-related molecular testing in patients with HR+/HER2– metastatic breast cancer.
At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

At the Crest of Innovation | Professors Jian Zhang and Songqing Ye Discuss the Frontiers of ADC Therapy in Breast Cancer

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian Provincial Hospital to engage in an in-depth discussion on the evolution of ADCs, recent clinical advances, toxicity management, and future trends. Drawing on cutting-edge clinical data and real-world experience, the two experts offer valuable insights into efficacy optimization, toxicity management, frontline integration, combination strategies, and drug diversification.
The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

The 8th Tongji Breast Cancer Forum | Professor Huihua Xiong: Integrating Top Academic Expertise to Advance Regional Breast Cancer Care

With the arrival of spring, the 8th Tongji Breast Cancer Forum was successfully convened, focusing on key topics including clinical needs, cutting-edge advances, grassroots implementation, and the development of young physicians. The meeting not only built a bridge for in-depth dialogue between leading experts and frontline clinicians, but also offered fresh perspectives on integrating clinical practice with the latest scientific progress.
Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

Beijing · April 24–25 | 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (AOT 2026) to Convene

In order to comprehensively advance public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become pivotal forces in overcoming critical health challenges. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Symposium (Art of Transplant: Beijing Hematopoietic Stem Cell Transplantation Symposium, AOT 2026), hosted by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care, and organized by the National Clinical Research Center for Hematologic Diseases and the Institute of Hematology at Peking University, will be grandly held in Beijing on April 24–25, 2026.
Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

Professor Haixia Fu: Applications and Advances of TPO Receptor Agonists and ATRA in the Treatment of ITP

From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis, hosted by the Hematologic Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology, was successfully held in Beijing. The meeting brought together leading international and domestic experts, clinicians, and industry leaders to explore cutting-edge developments in thrombosis and hemostasis, hematologic malignancies, and immunology, while advancing academic exchange and innovation in the field.
Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

Expert Interview | Prof. Shilpa Gupta Decodes Urothelial Carcinoma In-Depth: China’s Strength, Global Collaboration and Future Breakthroughs in the ADC Era

In recent years, the rapid advancement of antibody-drug conjugates (ADCs) has completely reshaped the treatment paradigm across the entire disease course of urothelial carcinoma. Meanwhile, Chinese investigators and domestically developed innovative agents have gained ever-increasing influence in the global oncology landscape. Recently, we had the exclusive opportunity to interview Prof. Shilpa Gupta, a world-leading expert in urothelial carcinoma, Leading Principal Investigator of multiple pivotal international multicenter clinical trials from Cleveland Clinic. We conducted an in-depth, professional exchange with Prof. Gupta on core topics including the global positioning of China's clinical research in urological oncology, optimized pathways for cross-border research collaboration, the paradigm shift in diagnosis and treatment driven by ADCs, and the future disruptive breakthrough directions in the field. The following is the edited content of this interview.